Cargando…
Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities
Nucleolin (NCL) has been reported as a cellular receptor for the human respiratory syncytial virus (RSV). We studied the effects of re-purposing AS1411, an anti-cancer compound that binds cell surface NCL, as a possible novel strategy for RSV therapy in vitro and in vivo. AS1411 was administered to...
Autores principales: | Mastrangelo, Peter, Norris, Michael J., Duan, Wenming, Barrett, Edward G., Moraes, Theo J., Hegele, Richard G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620558/ https://www.ncbi.nlm.nih.gov/pubmed/28925950 http://dx.doi.org/10.3390/vaccines5030027 |
Ejemplares similares
-
Identification of RSV Fusion Protein Interaction Domains on the Virus Receptor, Nucleolin
por: Mastrangelo, Peter, et al.
Publicado: (2021) -
RSV Fusion: Time for a New Model
por: Mastrangelo, Peter, et al.
Publicado: (2013) -
Host and Viral Factors in Respiratory Syncytial Virus Infection
por: Mastrangelo, Peter, et al.
Publicado: (2013) -
Respiratory syncytial virus prolifically infects N2a neuronal cells, leading to TLR4 and nucleolin protein modulations and RSV F protein co-localization with TLR4 and nucleolin
por: Yuan, Xiaoling, et al.
Publicado: (2018) -
Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy
por: Brignole, Chiara, et al.
Publicado: (2021)